Biopharmaceutical Companies Working to Address One of the Most Common Chronic Health Problems in the US
America’s biopharmaceutical research companies are developing 92 innovative new medicines to help the millions of Americans affected by arthritis, according to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA). These medicines in development — all either in clinical trials or under review by FDA — include 55 for rheumatoid arthritis, 15 for musculoskeletal pain, 10 for osteoarthritis and 7 for psoriatic arthritis.
Arthritis is part of a group of related musculoskeletal diseases consisting of more than 100 different conditions that affect more than 52 million people in the US, according to the US Centers for Disease Control and Prevention (CDC). The new report conveys a variety of novel approaches building on our growing knowledge of disease and scientific progress to tackle this challenging chronic disease. Examples include
• A medicine for ankylosing spondylitis selectively binds to and neutralises a protein which causes inflammation and affects bone biology.
• A medicine for osteoarthritis combines two monoclonal antibodies allowing the medicine to target two different pro-inflammatory proteins.
• A medicine for psoriatic arthritis prevents a protein from exerting its full effect leading to possible inflammation.
• A medicine for rheumatoid arthritis targets the receptor of a stimulating factor that is key in the inflammatory process.
There are currently 155 active clinical trials for arthritis in the US, including 97 that have not yet started recruiting patients or have just begun to seek volunteers to participate. The development of new, innovative therapies would not be possible without the patients who volunteer to participate in clinical trials. These trials, in combination with the promising new scientific approaches researchers are using, build on the progress against arthritis.
Therapeutic advances have transformed the rheumatoid arthritis treatment paradigm over the last 20 years, from focusing on symptom management to now aiming for slowed disease progression and even disease remission. Disease-modifying biological medicines have ushered in a new age of treatment by targeting the cells involved in the progression of the disease. These medicines have dramatically slowed or even reversed the negative physical effects associated with the disease and made clinical remission possible for patients with severe rheumatoid arthritis.
To build on this momentum, PhRMA, 10 biopharmaceutical companies and several non-profit disease foundations joined the National Institutes of Health in partnership to explore promising new technologies together and to address tough scientific problems that may lead to advances against our most costly and challenging diseases through the Accelerating Medicines Partnership (AMP). AMP is working to transform the current model for developing diagnostics and treatments by jointly identifying and validating promising biological targets of disease. The autoimmune diseases of rheumatoid arthritis and systemic lupus erythematosus were chosen as the focus of one of three initial pilot programmes.
“Biopharmaceutical research companies are working with partners across the ecosystem to bring treatments to help ease the pain and suffering caused by arthritis, but challenges remain,” said PhRMA President and CEO John J. Castellani. “The 92 medicines in the pipeline today offer tremendous hope for patients looking for new solutions to one of the most common chronic health conditions.”
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance